QQQ   352.52 (+1.30%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   399.99 (+5.72%)
NIO   7.58 (+0.66%)
BABA   83.89 (+5.46%)
AMD   120.31 (+1.78%)
T   15.79 (+0.38%)
F   12.13 (+1.08%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.60%)
GE   105.06 (+3.48%)
DIS   88.58 (+0.70%)
AMC   4.61 (+2.44%)
PFE   37.97 (-0.13%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
QQQ   352.52 (+1.30%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   399.99 (+5.72%)
NIO   7.58 (+0.66%)
BABA   83.89 (+5.46%)
AMD   120.31 (+1.78%)
T   15.79 (+0.38%)
F   12.13 (+1.08%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.60%)
GE   105.06 (+3.48%)
DIS   88.58 (+0.70%)
AMC   4.61 (+2.44%)
PFE   37.97 (-0.13%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
QQQ   352.52 (+1.30%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   399.99 (+5.72%)
NIO   7.58 (+0.66%)
BABA   83.89 (+5.46%)
AMD   120.31 (+1.78%)
T   15.79 (+0.38%)
F   12.13 (+1.08%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.60%)
GE   105.06 (+3.48%)
DIS   88.58 (+0.70%)
AMC   4.61 (+2.44%)
PFE   37.97 (-0.13%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
QQQ   352.52 (+1.30%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   399.99 (+5.72%)
NIO   7.58 (+0.66%)
BABA   83.89 (+5.46%)
AMD   120.31 (+1.78%)
T   15.79 (+0.38%)
F   12.13 (+1.08%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.60%)
GE   105.06 (+3.48%)
DIS   88.58 (+0.70%)
AMC   4.61 (+2.44%)
PFE   37.97 (-0.13%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
NASDAQ:RGEN

Repligen (RGEN) Stock Forecast, Price & News

$167.12
-0.80 (-0.48%)
(As of 02:27 PM ET)
Compare
Today's Range
$163.07
$168.00
50-Day Range
$145.15
$180.31
52-Week Range
$137.65
$262.26
Volume
336,754 shs
Average Volume
570,849 shs
Market Capitalization
$9.31 billion
P/E Ratio
56.65
Dividend Yield
N/A
Price Target
$208.56

Repligen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
27.2% Upside
$208.56 Price Target
Short Interest
Bearish
10.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.30
Upright™ Environmental Score
News Sentiment
1.23mentions of Repligen in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$158,665 Bought Last Quarter
Proj. Earnings Growth
27.43%
From $2.37 to $3.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.86 out of 5 stars

Medical Sector

247th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

35th out of 330 stocks


RGEN stock logo

About Repligen (NASDAQ:RGEN) Stock

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Stock News Headlines

Repligen (NASDAQ: RGEN)
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
StockNews.com Begins Coverage on Repligen (NASDAQ:RGEN)
RBC Capital Sticks to Its Hold Rating for Repligen (RGEN)
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
Repligen (NASDAQ:RGEN) Updates FY23 Earnings Guidance
Repligen (NASDAQ:RGEN) PT Lowered to $210.00
Q1 2023 Repligen Corp Earnings Call
Repligen (RGEN) Scheduled to Post Earnings on Tuesday
See More Headlines

RGEN Price History

RGEN Company Calendar

Last Earnings
5/02/2023
Today
6/01/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
2,025
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$208.56
High Stock Price Forecast
$275.00
Low Stock Price Forecast
$157.00
Forecasted Upside/Downside
+27.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$185.96 million
Pretax Margin
25.24%

Debt

Sales & Book Value

Annual Sales
$801.54 million
Cash Flow
$4.09 per share
Book Value
$34.85 per share

Miscellaneous

Free Float
55,068,000
Market Cap
$9.08 billion
Optionable
Optionable
Beta
1.08

Social Links


Key Executives

  • Tony J. Hunt
    President, Chief Executive Officer & Director
  • James R. BylundJames R. Bylund
    Chief Operating Officer
  • Jon K. SnodgresJon K. Snodgres
    Chief Financial & Accounting Officer
  • Ralf KuriyelRalf Kuriyel
    Senior Vice President-Research & Development
  • Vikas Gupta
    VP & GM-Downstream Bioprocessing & Gene Therapy













RGEN Stock - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price forecast for 2023?

8 Wall Street research analysts have issued 1 year target prices for Repligen's shares. Their RGEN share price forecasts range from $157.00 to $275.00. On average, they predict the company's stock price to reach $208.56 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2023?

Repligen's stock was trading at $169.31 at the start of the year. Since then, RGEN stock has decreased by 3.7% and is now trading at $163.07.
View the best growth stocks for 2023 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our RGEN earnings forecast
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings data on Tuesday, May, 2nd. The biotechnology company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.05. The biotechnology company earned $182.70 million during the quarter, compared to analyst estimates of $181.43 million. Repligen had a trailing twelve-month return on equity of 9.14% and a net margin of 21.58%. Repligen's revenue was down 11.5% compared to the same quarter last year. During the same period last year, the business posted $0.92 EPS.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY23 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $2.35-$2.42 for the period, compared to the consensus estimate of $2.64. The company issued revenue guidance of $720-$760 million, compared to the consensus revenue estimate of $779.97 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.76%), State Street Corp (2.94%), Sands Capital Management LLC (2.90%), Wellington Management Group LLP (2.68%), Brown Capital Management LLC (2.59%) and Artisan Partners Limited Partnership (2.19%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends
.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $163.07.

How much money does Repligen make?

Repligen (NASDAQ:RGEN) has a market capitalization of $9.08 billion and generates $801.54 million in revenue each year. The biotechnology company earns $185.96 million in net income (profit) each year or $2.95 on an earnings per share basis.

How many employees does Repligen have?

The company employs 2,025 workers across the globe.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.

This page (NASDAQ:RGEN) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -